MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The non-exclusive license grants Adicet Bio research, clinical, and commercial rights to support their gamma delta T cell therapy gene edited programs.
Under the agreement, MaxCyte will receive platform licensing fees and program-related revenue. Adicet Bio will utilize MaxCyte's technology to enhance their proprietary manufacturing process for allogeneic gamma delta T cell therapies, aimed at treating cancer and autoimmune diseases.
The collaboration leverages MaxCyte's ExPERT™ platform, which provides high transfection efficiency, cell viability, and seamless scalability for complex cell engineering applications.
MaxCyte (NASDAQ:MXCT) ha firmato un accordo strategico di licenza per la piattaforma con Adicet Bio per l'utilizzo della tecnologia Flow Electroporation® di MaxCyte e della piattaforma ExPERT™. La licenza non esclusiva concede ad Adicet Bio i diritti di ricerca, clinici e commerciali per supportare i loro programmi di terapia con cellule T gamma delta modificate geneticamente.
Secondo l'accordo, MaxCyte riceverà compensi per la licenza della piattaforma e ricavi legati ai programmi. Adicet Bio utilizzerà la tecnologia di MaxCyte per migliorare il proprio processo di produzione proprietario delle terapie con cellule T gamma delta allogeniche, destinate al trattamento di tumori e malattie autoimmuni.
La collaborazione sfrutta la piattaforma ExPERT™ di MaxCyte, che garantisce alta efficienza di trasfezione, vitalità cellulare e scalabilità fluida per applicazioni complesse di ingegneria cellulare.
MaxCyte (NASDAQ:MXCT) ha firmado un acuerdo estratégico de licencia de plataforma con Adicet Bio para el uso de la tecnología Flow Electroporation® de MaxCyte y la plataforma ExPERT™. La licencia no exclusiva otorga a Adicet Bio derechos de investigación, clínicos y comerciales para apoyar sus programas de terapia con células T gamma delta editadas genéticamente.
Según el acuerdo, MaxCyte recibirá tarifas por licencia de plataforma y ingresos relacionados con los programas. Adicet Bio utilizará la tecnología de MaxCyte para mejorar su proceso de fabricación propietario de terapias con células T gamma delta alogénicas, dirigidas al tratamiento del cáncer y enfermedades autoinmunes.
La colaboración aprovecha la plataforma ExPERT™ de MaxCyte, que ofrece alta eficiencia de transfección, viabilidad celular y escalabilidad sin inconvenientes para aplicaciones complejas de ingeniería celular.
MaxCyte (NASDAQ:MXCT)는 Adicet Bio와 MaxCyte의 Flow Electroporation® 기술 및 ExPERT™ 플랫폼 사용을 위한 전략적 플랫폼 라이선스 계약을 체결했습니다. 비독점 라이선스는 Adicet Bio에 감마 델타 T 세포 유전자 편집 치료 프로그램을 지원하기 위한 연구, 임상 및 상업적 권리를 부여합니다.
계약에 따라 MaxCyte는 플랫폼 라이선스 수수료와 프로그램 관련 수익을 받게 됩니다. Adicet Bio는 MaxCyte의 기술을 활용하여 암 및 자가면역 질환 치료를 목표로 하는 동종 감마 델타 T 세포 치료제의 독자적 제조 공정을 향상시킬 예정입니다.
이번 협력은 높은 형질도입 효율, 세포 생존율 및 복잡한 세포 공학 응용 분야에 대한 원활한 확장성을 제공하는 MaxCyte의 ExPERT™ 플랫폼을 기반으로 합니다.
MaxCyte (NASDAQ:MXCT) a signé un accord de licence stratégique de plateforme avec Adicet Bio pour l'utilisation de la technologie Flow Electroporation® de MaxCyte et de la plateforme ExPERT™. Cette licence non exclusive accorde à Adicet Bio des droits de recherche, cliniques et commerciaux pour soutenir leurs programmes de thérapie cellulaire T gamma delta modifiée génétiquement.
Dans le cadre de cet accord, MaxCyte percevra des frais de licence de plateforme ainsi que des revenus liés aux programmes. Adicet Bio utilisera la technologie de MaxCyte pour améliorer son processus de fabrication propriétaire des thérapies cellulaires T gamma delta allogéniques, destinées au traitement du cancer et des maladies auto-immunes.
Cette collaboration s'appuie sur la plateforme ExPERT™ de MaxCyte, qui offre une haute efficacité de transfection, une viabilité cellulaire et une évolutivité fluide pour des applications complexes d'ingénierie cellulaire.
MaxCyte (NASDAQ:MXCT) hat eine strategische Plattformlizenzvereinbarung mit Adicet Bio für die Nutzung der Flow Electroporation®-Technologie und der ExPERT™-Plattform von MaxCyte unterzeichnet. Die nicht-exklusive Lizenz gewährt Adicet Bio Forschungs-, klinische und kommerzielle Rechte zur Unterstützung ihrer genetisch bearbeiteten Gamma-Delta-T-Zell-Therapieprogramme.
Im Rahmen der Vereinbarung erhält MaxCyte Lizenzgebühren für die Plattform sowie programmbezogene Einnahmen. Adicet Bio wird die Technologie von MaxCyte nutzen, um ihren proprietären Herstellungsprozess für allogene Gamma-Delta-T-Zell-Therapien zu verbessern, die zur Behandlung von Krebs und Autoimmunerkrankungen entwickelt werden.
Die Zusammenarbeit nutzt die ExPERT™-Plattform von MaxCyte, die eine hohe Transfektionseffizienz, Zellviabilität und nahtlose Skalierbarkeit für komplexe zelluläre Engineering-Anwendungen bietet.
- New strategic platform license agreement expands MaxCyte's technology reach
- Agreement provides additional revenue stream through licensing fees and program-related payments
- Partnership validates MaxCyte's ExPERT platform capabilities in cell therapy development
- None.
Insights
MaxCyte's platform license with Adicet Bio provides revenue opportunities while expanding their technology's footprint in the growing cell therapy market.
This strategic platform license agreement represents a notable expansion of MaxCyte's technology footprint in the cell therapy space. The deal grants Adicet Bio non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for their gamma delta T cell therapy development pipeline across research, clinical, and commercial applications.
The financial structure follows MaxCyte's established business model, with the company receiving
The partnership highlights the versatility and industry validation of MaxCyte's ExPERT™ platform. By enabling non-viral gene editing delivery for Adicet's allogeneic gamma delta T cell therapies, MaxCyte strengthens its position in the rapidly growing cell therapy market, particularly in approaches that may offer manufacturing advantages over traditional CAR-T therapies.
For MaxCyte, this agreement adds to their portfolio of strategic platform licenses with biotech companies, diversifying their revenue potential across multiple therapeutic programs. The deal aligns with their business strategy of providing enabling technologies that support the advancement of next-generation cell therapies while capturing value through licensing arrangements rather than assuming direct clinical development risks.
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs
ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, Inc., a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
Adicet Bio has developed a proprietary manufacturing process to activate and expand distinct subsets of gamma delta T cells, enabling scalable production of its off-the-shelf, allogeneic cell therapies for use on demand in the clinical setting. The company’s approach combines non-viral gene editing with a robust expansion platform to deliver potent cell therapy products with the potential to treat a broad range of cancers and autoimmune disorders.
“We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility.”
MaxCyte’s ExPERT™ instrument portfolio represents the next generation of clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Specifically, there is no assurance that MaxCyte will receive additional program-related revenue or other revenue under this SPL.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
What is the new licensing agreement between MaxCyte (MXCT) and Adicet Bio?
How will MaxCyte (MXCT) generate revenue from the Adicet Bio agreement?
What will Adicet Bio use MaxCyte's (MXCT) technology for?
What are the key features of MaxCyte's ExPERT platform?
Who is the CEO of MaxCyte (MXCT) in this announcement?
